Blog
RSS FeedPosted by Michael Wonder on 20 May 2019
Europe responding to gene therapy challenge, but picture remains fragmented
20 May 2019 - Germany, Italy and England using outcomes-based deals. ...
Posted by Michael Wonder on 20 May 2019
ICER plans cloud-based tools to accelerate the use of value assessments in the US health care system
20 May 2019 - With a late 2019 launch target, ICER’s Evidence Compendium and Interactive Modeler will enable decision-makers within payers, ...
Posted by Michael Wonder on 10 May 2019
What do transformational shifts mean in terms of ultimate outcomes and ‘value’ of medicines?
9 May 2019 - Emerging ‘one-time’ curative therapies create important new options for patients living with difficult and incurable health ...
Posted by Michael Wonder on 02 May 2019
ICER seeks public input for 2020 value assessment framework
2 May 2019 - Accepting Open Input Through 10 June 2019. ...
Posted by Michael Wonder on 01 May 2019
Drug maker Takeda to introduce value-based pricing in Europe
29 April 2019 - Japanese company to refund Crohn's disease patients with no improvements. ...
Posted by Michael Wonder on 12 Apr 2019
Addressing health system values in health technology assessment: the use of evidence-informed deliberative processes
8 April 2019 - Health technology assessment is increasingly used around the globe to inform resource allocation decisions. Furthermore, the importance ...
Posted by Michael Wonder on 11 Apr 2019
The perils of value based pricing for prescription drugs
11 April 2019 - How do you determine the value, and the price, of life-saving medication? ...
Posted by Michael Wonder on 11 Apr 2019
The role of regulators in establishing added benefit of novel therapies
11 April 2019 - Regulators have a role to play in ensuring that there is a solid evidence base to support ...
Posted by Michael Wonder on 08 Apr 2019
Value-based agreements could disrupt how we pay for new therapies
8 April 2019 - On Tuesday, the Senate Finance Committee will hold its second hearing in a series on drug ...
Posted by Michael Wonder on 02 Apr 2019
When is the price of a drug unjust? The average lifetime earnings standard
1 April 2019 - The majority of Americans believe that lowering drug prices should be the top health care priority for ...
Posted by Michael Wonder on 27 Mar 2019
Outcomes based pricing not a panacea for high priced drugs
27 March 2019 - In the battle over the pricing of new drugs, manufacturers and payers have sought to come ...
Posted by Michael Wonder on 12 Mar 2019
Overview of cost-effectiveness analysis
11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...
Posted by Michael Wonder on 07 Mar 2019
Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain
7 March 2019 - To make medicines more affordable, President Trump insists that “foreign freeloading” must end. ...
Posted by Michael Wonder on 05 Mar 2019
Evaluating Canadians’ values for drug coverage decision making
2 March 2019 - Decision makers are facing growing challenges in prioritising drugs for reimbursement because of soaring drug costs and ...
Posted by Michael Wonder on 05 Mar 2019
Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany
5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...